Global tuberculosis targets and milestones set for 2016-2035: definition and rationale

被引:76
作者
Floyd, K. [1 ]
Glaziou, P. [1 ]
Houben, R. M. G. J. [2 ]
Sumner, T. [2 ]
White, R. G. [2 ]
Raviglione, M. [1 ]
机构
[1] WHO, Global TB Programme, Geneva, Switzerland
[2] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England
关键词
TB; control; strategy; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; BURDEN;
D O I
10.5588/ijtld.17.0835
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BACKGROUND: Global tuberculosis (TB) targets were set as part of the World Health Organization's End TB Strategy (2016-2035) and the Sustainable Development Goals (2016-2030). OBJECTIVE : To define and explain the rationale for these targets. DES IGN: Scenarios for plausible reductions in TB deaths and cases were developed using empirical evidence from best-performing countries and modelling of the scale-up of under-used interventions and hypothetical TB vaccines. Results were discussed at consultations in 2012 and 2013. A final proposal was presented to the World Health Assembly in 2014 and unanimously endorsed by all Member States. RESULT S : The 2030 targets are a 90% reduction in TB deaths and 80% reduction in TB incidence compared with 2015 levels. The 2035 targets are for reductions of 95% and 90%, respectively. A third target-that no TBaffected households experience catastrophic costs due to the disease by 2020-was also agreed. CONCLUSION: The global TB targets and milestones set for the period 2016-2035 are ambitious. Achieving them requires concerted action on several fronts, but two things are fundamental: 1) progress towards universal health coverage to ensure that everyone with TB can access high-quality treatment; and 2) substantial investment in research and development for new tools to prevent TB disease among the approximately 1.7 billion people infected.
引用
收藏
页码:723 / +
页数:19
相关论文
共 37 条
  • [1] Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Abu-Raddad, Laith J.
    Sabatelli, Lorenzo
    Achterberg, Jerusha T.
    Sugimoto, Jonathan D.
    Longini, Ira M., Jr.
    Dye, Christopher
    Halloran, M. Elizabeth
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (33) : 13980 - 13985
  • [2] Treatment of latent tuberculosis infection in HIV infected persons
    Akolo, Christopher
    Adetifa, Ifedayo
    Shepperd, Sasha
    Volmink, Jimmy
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [3] [Anonymous], 2015, Tracking universal health coverage: first global monitoring report
  • [4] [Anonymous], LANG ENV STAT COMP
  • [5] [Anonymous], 2015, Global Tuberculosis Report
  • [6] [Anonymous], 2009, TB impact measurement: Policy and recommendations for how to assess the epidemiological burden of TB and the impact of TB control
  • [7] [Anonymous], WORLD POP PROSP 2010
  • [8] [Anonymous], 2011, World Population Prospects: The 2010 Revision
  • [9] Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli
    Behr, MA
    Warren, SA
    Salamon, H
    Hopewell, PC
    de Leon, AP
    Daley, CL
    Small, PM
    [J]. LANCET, 1999, 353 (9151) : 444 - 449
  • [10] THE INTRINSIC TRANSMISSION DYNAMICS OF TUBERCULOSIS EPIDEMICS
    BLOWER, SM
    MCLEAN, AR
    PORCO, TC
    SMALL, PM
    HOPEWELL, PC
    SANCHEZ, MA
    MOSS, AR
    [J]. NATURE MEDICINE, 1995, 1 (08) : 815 - 821